Spyre Therapeutics to Participate in Upcoming March Investor Conferences

GlobeNewswire

Feb 25

WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced that management will participate in the following upcoming investor conferences:

Event: TD Cowen 46th Annual Health Care Conference - Boston
Date: Tuesday, March 3, 2026
Presentation and Fireside Time: 3:10 pm ET

Event: Leerink Global Healthcare Conference – Miami
Date: Monday, March 9, 2026
Fireside Time: 8:40 am ET

Event: Jefferies Biotech on the Beach Summit – Miami
Date: Tuesday, March 10, 2026

Members of the Spyre management team will host one-on-one investor meetings during the conferences.

Live audio webcasts and replays of these events will be available on the Spyre investor events website at https://ir.spyre.com/events-and-presentations.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.

For more information, visit Spyre's website at www.spyre.com.

For Investors:
Eric McIntyre, Spyre Therapeutics
SVP of Finance and Investor Relations
Eric.mcintyre@spyre.com

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2614726643"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614726643\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614726643?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-25 05:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614726643","market":"hk","top_or_hot":-1,"title":"Spyre Therapeutics to Participate in Upcoming March Investor Conferences","media":"GlobeNewswire","content":"<html><body><p>WALTHAM, Mass., Feb.  24, 2026  (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/SYRE\">Spyre Therapeutics</a>, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced that management will participate in the following upcoming investor conferences:</p> <p><strong>Event: TD Cowen 46th Annual Health Care Conference - Boston</strong><br/><strong>Date: </strong>Tuesday, March 3, 2026<br/><strong>Presentation and Fireside Time: </strong>3:10 pm ET</p> <p><strong>Event: Leerink Global Healthcare Conference – Miami</strong><br/><strong>Date: </strong>Monday, March 9, 2026<br/><strong>Fireside Time: </strong>8:40 am ET</p> <p><strong>Event: Jefferies Biotech on the Beach <a href=\"https://laohu8.com/S/SMMT\">Summit</a> – Miami</strong><br/><strong>Date: </strong>Tuesday, March 10, 2026</p> <p>Members of the Spyre management team will host one-on-one investor meetings during the conferences.</p> <p>Live audio webcasts and replays of these events will be available on the Spyre investor events website at https://ir.spyre.com/events-and-presentations.</p> <p><strong>About Spyre <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a></strong></p> <p>Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.</p> <p>For more information, visit Spyre's website at www.spyre.com.</p> <p><strong>For Investors:</strong>      <br/>Eric McIntyre, Spyre Therapeutics<br/>SVP of Finance and Investor Relations<br/>Eric.mcintyre@spyre.com</p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/ZjQ0MWQ0OTgtNTIwOC00ODJjLTg0YTItODI3MWRlMjBkZTcyLTEzMDYzNjMtMjAyNi0wMi0yNC1lbg==/tiny/Spyre-Therapeutics-Inc-.png\"/></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Spyre Therapeutics to Participate in Upcoming March Investor Conferences</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSpyre Therapeutics to Participate in Upcoming March Investor Conferences\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1016364462\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">GlobeNewswire </p>\n<p class=\"h-time\">2026-02-25 05:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>WALTHAM, Mass., Feb.  24, 2026  (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/SYRE\">Spyre Therapeutics</a>, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced that management will participate in the following upcoming investor conferences:</p> <p><strong>Event: TD Cowen 46th Annual Health Care Conference - Boston</strong><br/><strong>Date: </strong>Tuesday, March 3, 2026<br/><strong>Presentation and Fireside Time: </strong>3:10 pm ET</p> <p><strong>Event: Leerink Global Healthcare Conference – Miami</strong><br/><strong>Date: </strong>Monday, March 9, 2026<br/><strong>Fireside Time: </strong>8:40 am ET</p> <p><strong>Event: Jefferies Biotech on the Beach <a href=\"https://laohu8.com/S/SMMT\">Summit</a> – Miami</strong><br/><strong>Date: </strong>Tuesday, March 10, 2026</p> <p>Members of the Spyre management team will host one-on-one investor meetings during the conferences.</p> <p>Live audio webcasts and replays of these events will be available on the Spyre investor events website at https://ir.spyre.com/events-and-presentations.</p> <p><strong>About Spyre <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a></strong></p> <p>Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.</p> <p>For more information, visit Spyre's website at www.spyre.com.</p> <p><strong>For Investors:</strong>      <br/>Eric McIntyre, Spyre Therapeutics<br/>SVP of Finance and Investor Relations<br/>Eric.mcintyre@spyre.com</p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/ZjQ0MWQ0OTgtNTIwOC00ODJjLTg0YTItODI3MWRlMjBkZTcyLTEzMDYzNjMtMjAyNi0wMi0yNC1lbg==/tiny/Spyre-Therapeutics-Inc-.png\"/></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://www.globenewswire.com/news-release/2026/02/24/3244017/0/en/Spyre-Therapeutics-to-Participate-in-Upcoming-March-Investor-Conferences.html","article_id":"2614726643","we_media_id":"1016364462","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614726643","pubTimestamp":1771967100,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"GlobeNewswire","introduction":"Share your news with media, investors, and consumers with targeted distribution options from one of the world’s largest and most trusted newswires.","home_visible":1,"id":"1016364462","head_image":"https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a"},"summary":"WALTHAM, Mass., Feb.  24, 2026  (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redef","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","BK4539":"次新股","SYRE":"SPYRE THERAPEUTICS INC","BK4139":"生物科技","BK4007":"制药"},"translate_title":"Spyre Therapeutics将参加即将举行的3月份投资者会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"SYRE":1},"content_text":"WALTHAM, Mass., Feb.  24, 2026  (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced that management will participate in the following upcoming investor conferences: Event: TD Cowen 46th Annual Health Care Conference - BostonDate: Tuesday, March 3, 2026Presentation and Fireside Time: 3:10 pm ET Event: Leerink Global Healthcare Conference – MiamiDate: Monday, March 9, 2026Fireside Time: 8:40 am ET Event: Jefferies Biotech on the Beach Summit – MiamiDate: Tuesday, March 10, 2026 Members of the Spyre management team will host one-on-one investor meetings during the conferences. Live audio webcasts and replays of these events will be available on the Spyre investor events website at https://ir.spyre.com/events-and-presentations. About Spyre Therapeutics Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23. For more information, visit Spyre's website at www.spyre.com. For Investors:      Eric McIntyre, Spyre TherapeuticsSVP of Finance and Investor RelationsEric.mcintyre@spyre.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}